BrainChild Bio raises $116M series A for pediatric brain cancer CAR-T therapy
BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.
